close

News

LATEST POSTS from News

Vivet Therapeutics receives €4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis

Vivet Therapeutics receives €4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis  Funding from French Government as part of the France Health Innovation Plan 2030 Vivet Therapeutics, a French clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic disorders,…..

Clean Cells opens new production suites close to Nantes

Clean Cells opens new production suites close to Nantes Clean Cells, part of the Clean Biologics group, a French provider of biopharmaceutical product quality control services and manufacturer of starting materials, has launched operations in its new production suites, located in the new facility opened in January 2023, in Montaigu-Vendée,…..

DREAMS: a new Horizon Europe project combining AI and stem cells for the treatment of neuromuscular diseases

DREAMS: a new Horizon Europe project combining AI and stem cells for the treatment of neuromuscular diseases [caption id="attachment_11533" align="aligncenter" width="270"] ©ISTEM[/caption] In a groundbreaking endeavour set to span five years, the DREAMS consortium is paving the way for a novel approach to treating neuromuscular diseases. This transformative project merges…..

MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies

MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies • Major milestone achieved with new state-of-the-art microbiome facility spanning over 1600 m², completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe. • MaaT Pharma is…..

Advanced treatment for rare neurological “RASopathies”

Advanced treatment for rare neurological “RASopathies” Parents’ initiative for affected children leads to a new EU research project RASopathies are a group of genetic diseases triggered by increased activation of the cellular RAS-MAPK signal pathway. This signal pathway has a decisive influence on growth and the differentiation of our cells.…..